Clinical Trials Logo

Rhinitis clinical trials

View clinical trials related to Rhinitis.

Filter by:

NCT ID: NCT00817050 Completed - Allergic Rhinitis Clinical Trials

Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207)

Start date: December 1, 2004
Phase: Phase 4
Study type: Interventional

This was a one-day single dose trial conducted to compare patient's preference for Nasonex® (mometasone) versus Flonase® nasal spray. Each patient was randomized to take one dose (2 sprays in each nostril) of Nasonex or Flonase. Thirty minutes later, each patient was to take one dose of the opposite medication. Questionnaires were given to each patient after each drug dose to evaluate patient product preference.

NCT ID: NCT00816972 Completed - Clinical trials for Seasonal Allergic Rhinitis

Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)

Start date: April 2005
Phase: Phase 2
Study type: Interventional

This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.

NCT ID: NCT00807053 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to demonstrate the efficacy of ciclesonide HFA, applied as a nasal aerosol once daily, in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.

NCT ID: NCT00806754 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Start date: November 2006
Phase: Phase 4
Study type: Interventional

- The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with perennial allergic rhinitis (PAR) not adequately controlled on an intranasal corticosteroid or antihistamine monotherapy - The secondary objective is to investigate the safety of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray

NCT ID: NCT00805584 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)

Start date: May 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study was to test the effectiveness and side effects of desloratadine (Aerius) in patients with hayfever. Patients took desloratadine once a day for 15 days. At the end of therapy, they scored how severe their hayfever symptoms were and how they responded to therapy. Side effects were recorded.

NCT ID: NCT00805324 Completed - Asthma Clinical Trials

Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)

Start date: May 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study was to test the effectiveness and safety of desloratadine (Aerius) syrup in children with hayfever with or without asthma. Patients took desloratadine syrup once a day for 28 days. Once a week, the doctor measured the patient's hayfever symptoms. The doctor also rated how much relief the patient got from treatment and recorded any side effects.

NCT ID: NCT00804687 Completed - Allergic Rhinitis Clinical Trials

An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the relative efficacy of JNJ- 39220675 and pseudoephedrine compared to placebo (medication with no active ingredients) in participants with allergic rhinitis (inflammation of the nose due to exposure to allergens such as pollen, dust or animal hair).

NCT ID: NCT00794846 Completed - Clinical trials for Seasonal Allergic Rhinitis

Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)

Start date: December 2002
Phase: Phase 4
Study type: Interventional

This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.

NCT ID: NCT00794794 Completed - Allergic Rhinitis Clinical Trials

Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)

Start date: November 2004
Phase: Phase 3
Study type: Interventional

This study was conducted to compare the taste acceptability of Zyrtec syrup with desloratadine syrup in children. Children between 6 and 11 years of age received 5 mL of each syrup, separated by 15 to 20 minutes on a single day.

NCT ID: NCT00794768 Completed - Clinical trials for Seasonal Allergic Rhinitis

Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)

Start date: November 2002
Phase: Phase 4
Study type: Interventional

This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.